<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vicente E Torres, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            York Pei, MD, FRCPC, FACP, FASN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronald D Perrone, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah A Baumgarten, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3352363174">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiomyolipomas (AMLs) are neoplasms occurring in the kidney that are composed of varying amounts of tissues resembling blood vessels, smooth muscle, and adipose. The vast majority of AMLs are benign but malignant AMLs have been reported [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         Renal AMLs may either occur sporadically or in association with either tuberous sclerosis complex (TSC), sporadic lymphangioleiomyomatosis (LAM), or a combination (TSC-LAM).
        </p>
        <p>
         This topic will discuss the epidemiology, pathogenesis, clinical manifestations, and diagnosis of renal AMLs. Other related issues are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management and prognosis of renal AMLs (see
         <a class="medical medical_review" href="/z/d/html/90017.html" rel="external">
          "Renal angiomyolipomas (AMLs): Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney manifestations of TSC (see
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal AMLs associated with LAM (see
         <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Renal angiomyolipomas'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A general overview of TSC-LAM (see
         <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">
          "Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An evaluation of incidental lesions of the kidney (see
         <a class="medical medical_review" href="/z/d/html/116643.html" rel="external">
          "Evaluation of the incidental kidney lesion"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H681321783">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AMLs have been reported in 0.13 to 2.2 percent of asymptomatic adults who underwent imaging [
         <a href="#rid5">
          5,6
         </a>
         ]. In a population-based study of approximately 18,000 asymptomatic adults who underwent kidney ultrasound, renal AMLs were identified in 24 patients (0.13 percent) [
         <a href="#rid5">
          5
         </a>
         ]. In another study of approximately 2000 potential kidney donors who underwent computed tomography (CT) scans, renal AMLs were identified in 43 patients (2.2 percent) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Renal AMLs appear to be more common among females [
         <a href="#rid7">
          7
         </a>
         ]. In a study of over 2000 patients with tuberous sclerosis complex (TSC), 58 percent of the 1070 patients with AML(s) were female [
         <a href="#rid8">
          8
         </a>
         ]. In smaller studies that included few or no individuals with TSC, 78 to 82 percent of patients with AML were female [
         <a href="#rid9">
          9,10
         </a>
         ]. This female predominance may be related to the role of estrogen in fostering the growth of AMLs. (See
         <a class="local">
          'Additional pathogenetic mechanisms in females'
         </a>
         below.)
        </p>
        <p>
         The majority of AMLs (over 80 percent) are sporadic. The remainder are mostly associated with TSC; sporadic lymphangioleiomyomatosis (LAM), or a combination of LAM and TSC (TSC-LAM) likely account for a small minority of cases [
         <a href="#rid7">
          7
         </a>
         ]. In one study of patients with sporadic AMLs, approximately 5 percent of patients (all female) had four or more cysts on their chest CT, which suggested the possibility of undiagnosed LAM [
         <a href="#rid10">
          10
         </a>
         ]. However, a confirmation of the diagnosis of LAM was not part of the study methods.
        </p>
        <p>
         The prevalence of renal AMLs is markedly higher among patients with TSC [
         <a href="#rid8">
          8,11-13
         </a>
         ], and this prevalence increases with age [
         <a href="#rid7">
          7,11,12,14-20
         </a>
         ]. In an international, multicenter registry study (Tuberous Sclerosis registry to increase disease Awareness [TOSCA]), approximately one-half (52 percent) of over 2000 patients (age range 0 to 71 years) were found to have renal AMLs [
         <a href="#rid8">
          8
         </a>
         ]. Compared with patients who had a
         <em>
          TSC1
         </em>
         mutation, those who had a
         <em>
          TSC2
         </em>
         mutation were more likely to have a renal AML (59 versus 33 percent), have the AML identified at a younger age (13 versus 24 years), have an AML with a size &gt;3 cm (32 versus 12 percent), and have an AML that grew in size over time (24 versus 12 percent). (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
         The prevalence of renal AMLs in patients with sporadic LAM is also higher compared with the general population. Approximately 15 to 38 percent of patients with sporadic LAM have renal AMLs [
         <a href="#rid21">
          21-24
         </a>
         ]. Renal AMLs among patients with LAM also tend to be multiple and bilateral and are more common among patients with TSC-LAM compared with sporadic LAM (88 versus 29 percent in one cohort) [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Renal angiomyolipomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4008690602">
         <span class="h1">
          PATHOGENESIS AND HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AMLs belong to a family of tumors collectively referred to as "neoplasms with perivascular epithelioid differentiation" or "perivascular epithelioid cell tumors" or "PEComas" [
         <a href="#rid25">
          25
         </a>
         ]. AMLs are primarily composed of smooth muscle cells, adipocytes, and epithelioid cells.
        </p>
        <p>
         Tuberous sclerosis complex (TSC) genes function as tumor suppressor genes, and like in patients with TSC, many sporadic AMLs contain TSC mutations. (See
         <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">
          "Tuberous sclerosis complex: Genetics and pathogenesis", section on 'Mechanism of tumor formation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12581058">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The three cell types (smooth muscle cells, adipocytes, and epithelioid cells) appear to be derived from pericytes, which are mural cells that line the microcirculation (capillaries and venules) of the body. Their origin from pericytes is suggested by the fact that they all express pericyte markers (angiotensin II type 1 receptor, platelet-derived growth factor receptor-beta, desmin, alpha
         <em>
          -
         </em>
         smooth muscle actin, and vascular endothelial growth factor-receptor 2) but not the endothelial cell marker CD31 or the adipocyte marker S-100 [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         The vasculature within an AML is composed of neoplastic (smooth muscle cells and epithelioid cells) and nonneoplastic (endothelial cells) components. The endothelial cells lining the blood vessels do not appear to originate from pericytes and rather appear to develop independently [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Infrequently, AMLs may exhibit characteristics such as local infiltration, extension into the renal vein and/or inferior vena cava, multicentricity, regional lymph node involvement, and rapid local recurrence (if excised). However, the vast majority of lesions have benign characteristics and remain contained.
        </p>
        <p class="headingAnchor" id="H2203044684">
         <span class="h2">
          Additional pathogenetic mechanisms in females
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several clinical observations suggest that female sex hormones promote the growth of renal AMLs. These observations include the increased reported frequency and size of renal AMLs among females, and the increased risk of hemorrhagic complications and growth of AMLs during pregnancy [
         <a href="#rid28">
          28-32
         </a>
         ] or after treatment with exogenous hormone therapy [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3591945707">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         On histopathology, AMLs are composed of mature-appearing fat, thick-walled and poorly organized blood vessel-like structures, and smooth muscle-like structures in varying proportions [
         <a href="#rid34">
          34
         </a>
         ]. The smooth muscle cells may be seen as appearing to originate from the blood vessel wall in the form of a pinwheel. The blood vessels are thick-walled, similar to arteries, but lack the systematic architectural organization of normal vascular structures.
        </p>
        <p>
         Variations in histology are common. There are two major histologic variants of AMLs: classic and epithelioid  (
         <a class="graphic graphic_picture graphicRef90669" href="/z/d/graphic/90669.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid7">
          7,35,36
         </a>
         ]. In addition, there is a rare cystic variant, called angiomyolipoma with epithelial cysts (AMLEC), which is characterized by solid and cystic areas. Variants are distinguished from each other only by biopsy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classic variant
         </strong>
         – Most AMLs are classic variants [
         <a href="#rid37">
          37
         </a>
         ]. The major features of the classic variant include abnormally thick-walled vessels that lack a well-developed internal elastic lamina and varying amounts of spindle smooth-muscle cells and adipose tissue  (
         <a class="graphic graphic_picture graphicRef90669" href="/z/d/graphic/90669.html" rel="external">
          picture 1
         </a>
         ). Any one of the three cell types (ie, smooth muscle cells, adipocytes, and epithelioid cells) may predominate or be virtually absent. In general, epithelioid cells are sparse and make up fewer than 10 percent of cells in the classic variant [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Classic AMLs are benign but can be locally invasive, extending into the perirenal fat or, rarely, the collecting system, renal vein, or inferior vena cava and right atrium. Involvement of lymph nodes and/or the spleen is thought to represent multicentricity of origin rather than metastases, since such patients, in general, have no further disease progression on long-term follow-up [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epithelioid variant
         </strong>
         – The epithelioid variant always has an epithelioid cell component  (
         <a class="graphic graphic_picture graphicRef90669" href="/z/d/graphic/90669.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]. Epithelioid cells are characterized by an abundant eosinophilic and granular cytoplasm. There is no consensus on the percentage of epithelioid cells that is required to make a diagnosis of the epithelioid variant, with values ranging from 10 to 100 percent in published studies [
         <a href="#rid37">
          37,41
         </a>
         ]. Thus, epithelioid AMLs can be composed entirely of epithelioid cells (and lack blood vessels and fat, also called "fat-invisible AMLs") [
         <a href="#rid42">
          42
         </a>
         ]. Alternatively, they can contain variable amounts of adipose and muscle tissue with a significant epithelioid component (generally called "fat poor").
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An epithelial component is probably more common in patients who have TSC compared with patients who have sporadic AML. In one case series of approximately 200 patients, epithelioid variants were noted among 25 percent of patients with TSC compared with 6 percent among patients without TSC [
         <a href="#rid37">
          37
         </a>
         ]. TFE3 amplification is occasionally present in epithelioid tumors and may contribute to tumor pathogenesis [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Unlike the classic variant, the epithelioid variant may be malignant. Although this is infrequent, the risk is greater in patients who have TSC [
         <a href="#rid37">
          37,41,45
         </a>
         ]. Histologic features that suggest an increased risk for malignant transformation include ≥70 percent epithelioid cells, tumor size &gt;7 cm, vascular invasion, ≥2 mitotic figures per 10 high-power fields, atypical mitotic figures, and necrosis [
         <a href="#rid41">
          41,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Angiomyolipoma with epithelial cysts (AMLEC)
         </strong>
         – This is a rare cystic variant of AML characterized by solid and cystic areas. AMLEC is a benign lesion with no metastases or recurrence following surgical excision [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This variant is characterized by immunohistochemical positivity of the subepithelial stroma for melanocytic markers (HMB45 and melan-A) [
         <a href="#rid47">
          47
         </a>
         ]. These markers help to differentiate this lesion from other cystic renal neoplasms such as multilocular cystic renal cell carcinoma, cystic nephroma, and mixed epithelial and stromal tumor of the kidney.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2331704596">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of renal AMLs cause no symptoms [
         <a href="#rid7">
          7,9
         </a>
         ]. AMLs usually come to medical attention as an incidental finding on imaging performed for a different indication, or in the case of some tuberous sclerosis complex (TSC) patients, upon serial imaging performed for surveillance [
         <a href="#rid5">
          5-7,15,36,48
         </a>
         ].
        </p>
        <p>
         The clinical presentation of renal AMLs can differ depending upon whether AMLs are sporadic or associated with TSC [
         <a href="#rid34">
          34
         </a>
         ]. Patients who have sporadic AMLs present in the fourth, fifth, or sixth decade of life, whereas patients with TSC-associated AMLs present earlier, in the third and fourth decades, as a result of surveillance among such patients. Sporadic AMLs are generally solitary, small, and slow-growing. Conversely, TSC-associated AMLs can be large, multiple, bilateral, and have a tendency to grow. In the Tuberous Sclerosis registry to increase disease Awareness (TOSCA) study, among the patients who had TSC-associated renal AMLs, 88 percent had AMLs that were multiple in number and 84 percent had AMLs that were bilateral [
         <a href="#rid8">
          8
         </a>
         ]. One-third of the patients had AMLs that were &gt;3 cm in size. At a mean follow-up of 1.3 years, growth of the AMLs was observed among 21 percent of patients.
        </p>
        <p>
         Among patients who are symptomatic, features related to hemorrhage appear to be most common. These include abdominal or flank pain (associated with mass effect of the hemorrhage) and tenderness, hematuria, hypertension, anemia, and kidney function impairment [
         <a href="#rid7">
          7,11,20,49,50
         </a>
         ]. Hemorrhage is the most feared clinical complication of AMLs due to its severe nature, often resulting in significant pain, anemia, and sometimes, hemorrhagic shock [
         <a href="#rid51">
          51
         </a>
         ]. Renal AMLs are the most common cause of Wunderlich syndrome, a life-threatening, nontraumatic kidney hemorrhage into the subcapsular and perirenal spaces [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         The risk of significant hemorrhage is related to the size of the AMLs, degree of vascularity, the size of aneurysms within the AML, and their growth pattern (exophytic growth is associated with a higher risk than endophytic growth) [
         <a href="#rid53">
          53
         </a>
         ]. AMLs that are larger than 6 cm have a higher likelihood of hemorrhage [
         <a href="#rid54">
          54
         </a>
         ]. Increased vascularity and/or an intralesional aneurysm that is 5 mm or larger are also associated with an increased risk of hemorrhage [
         <a href="#rid53">
          53,55,56
         </a>
         ].
        </p>
        <p>
         In addition, the risk of bleeding is increased among pregnant females, possibly due to a risk of rapid growth induced by hormonal changes and/or increased circulating blood volume and cardiac output associated with pregnancy [
         <a href="#rid28">
          28-31
         </a>
         ]. (See
         <a class="local">
          'Additional pathogenetic mechanisms in females'
         </a>
         above.)
        </p>
        <p>
         Patients with extensive AMLs in association with TSC may develop chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (see
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex"
         </a>
         ). The most common cause of ESKD in such patients is nephrectomy or embolization required to treat symptomatic AMLs [
         <a href="#rid57">
          57
         </a>
         ]. CKD or ESKD in patients with sporadic AML is infrequent.
        </p>
        <p>
         Epithelioid AMLs can undergo malignant transformation, distant metastasis, and can be associated with local recurrence after removal.
        </p>
        <p class="headingAnchor" id="H2663490169">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of renal AML is usually made by imaging. A biopsy of the lesions is usually not necessary, unless the diagnosis is not clear upon imaging or if malignancy is suspected.
        </p>
        <p>
         Patients who have tuberous sclerosis complex (TSC), sporadic lymphangioleiomyomatosis (LAM), or a combination may have renal AMLs as part of their initial presentation. Thus, all patients will need to undergo further testing to identify underlying TSC. Some will also need to be tested for LAM or TSC-LAM.
        </p>
        <p class="headingAnchor" id="H1461389249">
         <span class="h2">
          When to suspect AML
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most AMLs do not produce symptoms and are diagnosed incidentally on abdominal imaging performed for an unrelated reason. However, AMLs should be suspected among patients who have symptoms and signs of retroperitoneal hemorrhage (eg, flank pain, hematuria, anemia) associated with a mass-like lesion in the kidney. In addition, patients with a history of TSC, LAM, or TSC-LAM who develop such symptoms and signs should be evaluated for a renal AML. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3130497413">
         <span class="h2">
          How to establish a diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of sporadic AML is usually made by imaging (magnetic resonance imaging [MRI] or CT). In most cases, ultrasound can suggest the diagnosis but is not sufficient to establish the diagnosis. If the diagnosis cannot be made with certainty by CT or MRI, then a needle-guided biopsy of the kidney lesion is appropriate.
        </p>
        <p class="headingAnchor" id="H4235250477">
         <span class="h3">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We preferably use MRI to establish the diagnosis of renal AML. Although not necessary to diagnose AML, administration of gadolinium contrast is used to determine the vascularity of the lesion and detect intratumoral aneurysms. When an MRI is not available or is inappropriate (eg, if the patient has contraindications to MRI or is unable to remain still for the duration of an MRI), then we perform unenhanced and contrast-enhanced CT. We perform an MRI (or CT) even among patients who had the diagnosis of AML suggested by ultrasound. (See
         <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">
          "Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging"
         </a>
         .)
        </p>
        <p>
         When obtained, MRI and CT should be preferentially performed using a kidney mass protocol (imaging before and at multiple times after the administration of intravenous contrast). The diagnosis of AML depends upon detection of fat within the lesion  (
         <a class="graphic graphic_diagnosticimage graphicRef143481" href="/z/d/graphic/143481.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid58">
          58-62
         </a>
         ]. Both MRI and CT are able to identify AMLs that are rich in fat. However, in the subset of AMLs (approximately 5 percent of sporadic lesions) that have a small amount of intralesional fat (ie, "fat-poor" AMLs) [
         <a href="#rid63">
          63
         </a>
         ], MRI may be more sensitive than CT [
         <a href="#rid42">
          42,64
         </a>
         ]. In lesions that lack fat (ie, "fat-invisible" AMLs), no imaging modality can reliably distinguish an AML from an atypical-appearing renal cell carcinoma (RCC) or other malignancy. In such cases, we perform a biopsy for a definitive diagnosis. (See
         <a class="local">
          'Biopsy if imaging is equivocal'
         </a>
         below.)
        </p>
        <p>
         By MRI, fat appears hyperintense (bright) on T1 and T2 sequences without fat saturation and hypointense (dark) on T1 and T2 sequences with fat saturation  (
         <a class="graphic graphic_diagnosticimage graphicRef134935" href="/z/d/graphic/134935.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef143482" href="/z/d/graphic/143482.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid42">
          42
         </a>
         ]. Multiparametric MRI (the use of a variety of sequences including diffusion weighting and chemical shift imaging, among others) can be helpful to more reliably distinguish fat-poor AMLs from other lesions. In a 2020 meta-analysis including over 2000 patients who had an MRI and histopathologic diagnosis of fat-poor AML, MRI had a sensitivity of 83 percent (95% CI 72-90 percent) and specificity of 90 percent (95% CI 84-94 percent) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Unenhanced CT can identify macroscopic fat in AMLs  (
         <a class="graphic graphic_diagnosticimage graphicRef143484" href="/z/d/graphic/143484.html" rel="external">
          image 4
         </a>
         ). Low attenuation values of less than -15 Hounsfield units (HU) in the region of interest are generally indicative of fat [
         <a href="#rid42">
          42
         </a>
         ]. Thinner slices (3 to 5 mm) may be required to detect fat within smaller AMLs. "Fat-poor" AMLs demonstrate high intrinsic attenuation and, after contrast administration, homogenous enhancement, and delayed washout  (
         <a class="graphic graphic_diagnosticimage graphicRef143489" href="/z/d/graphic/143489.html" rel="external">
          image 5
         </a>
         ). The addition of contrast does not improve sensitivity of the diagnosis of AML markedly but may be useful to distinguish AML from other kidney lesions. In a meta-analysis of over 2200 patients who underwent a CT and histopathologic diagnosis of fat-poor AML, CT had a sensitivity of 0.67 (95% CI 0.48-0.81) and a specificity of 0.97 (95% CI 0.89-0.99). The sensitivity estimates of unenhanced and contrast-enhanced CT were comparable (0.81 versus 0.78). However, the heterogeneity between the included studies was high, thereby reducing the confidence in these estimates.
        </p>
        <p>
         By ultrasound, fat is generally hyperechoic (or hyperreflective) with variable acoustic shadowing [
         <a href="#rid42">
          42,66
         </a>
         ]. However, the appearance on ultrasound of approximately 10 to 30 percent of RCCs is similar to that of AMLs  (
         <a class="graphic graphic_diagnosticimage graphicRef143490" href="/z/d/graphic/143490.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid67">
          67,68
         </a>
         ]. In addition, fat-poor AMLs do not have this characteristic hyperechoic appearance and, therefore, can be missed by ultrasound. Thus, using ultrasound for initial diagnosis of AML is usually suboptimal; patients require the diagnosis to be confirmed by MRI or CT. However, among patients already diagnosed with an AML by CT or MRI, ultrasound can be used for monitoring the size of the AML over time.
        </p>
        <p>
         The main diagnostic challenges by imaging arise for patients who have fat-poor AMLs (classic AML composed predominantly of smooth muscle) and fat-invisible AMLs (epithelioid AMLs). The absence of or limited amount of fat in such lesions limits the ability to diagnose them by imaging alone [
         <a href="#rid64">
          64,69
         </a>
         ]. Alternatively, the fat present within a lesion may be obscured by hemorrhage. The lack of classic appearance may lead to inability to fully distinguish them from RCCs (especially RCCs that invade renal sinus fat giving the appearance of fat in the peripheral part of the lesion) and oncocytomas. In such patients, who generally present with solid kidney masses that do not have an appearance of a classic AML or other lesions, we pursue a biopsy for diagnosis. (See
         <a class="local">
          'Biopsy if imaging is equivocal'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3715820538">
         <span class="h3">
          Biopsy if imaging is equivocal
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the diagnosis cannot be made with certainty by MRI or CT, we obtain an image-guided percutaneous core needle biopsy [
         <a href="#rid70">
          70
         </a>
         ]. However, if the lesion is highly suspicious for malignancy because of intratumoral necrosis, intratumoral calcifications, presence of lymphadenopathy, or metastasis, clinicians may elect to surgically remove the lesion rather than perform a diagnostic biopsy [
         <a href="#rid71">
          71
         </a>
         ]. Additional details regarding the biopsy and histopathologic findings are discussed at length elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'Biopsy'
         </a>
         .)
        </p>
        <p>
         Surgical exploration is an alternative among patients in whom percutaneous needle biopsy is not feasible or unsuccessful in securing a diagnosis [
         <a href="#rid70">
          70
         </a>
         ]. The risk of bleeding following needle biopsy of a minimal-fat AML does not appear to be higher than that of a biopsy for other kidney tumors.
        </p>
        <p>
         The differentiation of renal AML from RCC has become more reliable with the aid of immunocytochemical analysis. Melanocytic markers such as HMB-45 and melan-A are expressed in classic and epithelioid renal AMLs but not in typical RCCs, while epithelial cell-associated markers such as cytokeratin and epithelial membrane antigen are present in RCCs but not in renal AMLs [
         <a href="#rid35">
          35,72-74
         </a>
         ]. A rare variant of RCC with a translocation t(6;11)(p21;q12) expresses HMB-45 and melan-A and is often negative or only focally positive for cytokeratin [
         <a href="#rid75">
          75-77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4221065260">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with AML may need additional evaluation for TSC or LAM.
        </p>
        <p class="headingAnchor" id="H4207342832">
         <span class="h3">
          Evaluate for tuberous sclerosis complex in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We evaluate all patients with newly diagnosed AML for possible TSC.
        </p>
        <p>
         The extent of the evaluation depends on the index of suspicion for TSC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic adult patients who have one or two small (ie, &lt;4 cm) AMLs are less likely to have TSC. Among such patients, it is sufficient to complete a clinical evaluation by obtaining a family history and performing a review of systems and a physical examination. The clinical diagnostic criteria of TSC are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">
          "Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with multiple (three or more), bilateral, or larger (ie, ≥4 cm) AMLs are more likely to have TSC  (
         <a class="graphic graphic_diagnosticimage graphicRef143482" href="/z/d/graphic/143482.html" rel="external">
          image 3
         </a>
         ). Among such patients, we perform a complete evaluation for TSC (which includes both a clinical evaluation and genetic testing). The diagnostic criteria for TSC are based upon specific clinical features that are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">
          "Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Among patients who undergo biopsy, histologic features may also help to distinguish sporadic from TSC-related AMLs. In a single-institution study of 194 renal AMLs in 185 patients, three histologic markers were observed more frequently in patients with TSC: epithelioid-variant AMLs, epithelial kidney cysts, and microscopic AML foci [
         <a href="#rid37">
          37
         </a>
         ]. However, the utility of such markers in identifying patients with TSC has not been proven.
        </p>
        <p class="headingAnchor" id="H2506166460">
         <span class="h3">
          Evaluate for lymphangioleiomyomatosis in some patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not evaluate all patients who present with a sporadic AML for pulmonary LAM. Only a small percentage of patients presenting with a sporadic AML have LAM  (
         <a class="graphic graphic_diagnosticimage graphicRef143491" href="/z/d/graphic/143491.html" rel="external">
          image 7
         </a>
         ). Instead, we would evaluate such patients for LAM only if suggestive findings (ie, pulmonary symptoms, abnormal chest radiograph) were present. (See
         <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p>
         Conversely, all patients who have LAM should be evaluated for renal AMLs. Approximately 45 to 60 percent of patients with sporadic pulmonary LAM have renal AMLs that tend to be multiple and bilateral [
         <a href="#rid21">
          21-24
         </a>
         ]. The clinical manifestations, diagnosis, and treatment of renal AMLs associated with sporadic pulmonary LAM are similar to those described for renal AMLs associated with TSC. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'Angiomyolipomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1342665019">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/120578.html" rel="external">
          "Society guideline links: Tuberous sclerosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1997609493">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Angiomyolipomas (AMLs) are uncommon neoplasms occurring in the kidney that are composed of varying amounts of tissues resembling blood vessels, smooth muscle, and adipose. The vast majority of AMLs are benign but malignant transformation of AMLs has been reported. Most AMLs are sporadic. The remainder are mostly associated with tuberous sclerosis complex (TSC); sporadic lymphangioleiomyomatosis (LAM) or a combination of LAM and TSC (TSC-LAM) likely account for a small minority of cases. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis and histology
         </strong>
         – AMLs are primarily composed of smooth muscle cells, adipocytes, and epithelioid cells. These three cell types appear to be derived from pericytes, which are mural cells that line the microcirculation (capillaries and venules) of the body. The vasculature within an AML is composed of neoplastic (smooth muscle cells and epithelioid cells) and nonneoplastic (endothelial cells) components. The endothelial cells lining the blood vessels do not appear to originate from pericytes and rather appear to develop independently. Several clinical observations suggest that female sex hormones promote the growth of renal AMLs. (See
         <a class="local">
          'Pathogenesis and histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are two major histologic variants of AMLs: classic and epithelioid  (
         <a class="graphic graphic_picture graphicRef90669" href="/z/d/graphic/90669.html" rel="external">
          picture 1
         </a>
         ). In addition, there is a rare cystic variant, called angiomyolipoma with epithelial cysts (AMLEC), which is characterized by solid and cystic areas. Variants are distinguished from each other only by biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Classic variant
         </strong>
         – Most AMLs are classic variants. In general, epithelioid cells are sparse and make up fewer than 10 percent of cells in the classic variant. Classic AMLs are benign but can be locally invasive, extending into the perirenal fat or, rarely, the collecting system, renal vein, or inferior vena cava and right atrium.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Epithelioid variant
         </strong>
         – The epithelioid variant always has an epithelioid cell component. There is no consensus on the percentage of epithelioid cells that is required to make a diagnosis of the epithelioid variant, with values ranging from 10 to 100 percent. Thus, epithelioid AMLs can be composed entirely of epithelioid cells (and lack blood vessels and fat, also called "fat-invisible AMLs"). Alternatively, they can contain variable amounts of adipose and muscle tissue with a significant epithelioid component (generally called "fat poor"). Unlike the classic variant, the epithelioid variant may undergo malignant transformation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The vast majority of renal AMLs cause no symptoms. AMLs usually come to medical attention as an incidental finding on imaging performed for a different indication, or in the case of some TSC patients, upon serial imaging performed for surveillance. Among patients who are symptomatic, features related to hemorrhage appear to be most common. These include abdominal or flank pain and tenderness, hematuria, hypertension, anemia, and kidney function impairment. Hemorrhage is the most feared clinical complication of AMLs due to its severe nature, often resulting in significant pain, anemia, and sometimes, hemorrhagic shock. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of sporadic AML is usually made by imaging, preferably MRI with gadolinium contrast. CT without and with contrast enhancement is reasonable when an MRI is not available or is inappropriate. Although ultrasound can suggest the diagnosis, it is not sufficient to establish the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The main diagnostic challenges by imaging arise for patients who have fat-poor or fat-invisible AMLs. The absence of or limited amount of fat in such lesions limits the ability to diagnose them by imaging alone. In addition, the fat present within a lesion may be obscured by hemorrhage. The lack of classic appearance may lead to the inability to fully distinguish such AMLs from renal cell carcinomas (RCCs). If the diagnosis cannot be made with certainty by MRI or CT, then we obtain an image-guided core needle biopsy of the kidney lesion. Surgical exploration is an alternative among patients in whom percutaneous needle biopsy is not feasible or unsuccessful in securing a diagnosis, or if the patient has features suspicious for malignancy (eg, intratumoral necrosis, intratumoral calcifications, presence of lymphadenopathy, or metastasis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postdiagnostic evaluation
         </strong>
         – We evaluate all patients with newly diagnosed AML for possible TSC. The extent of the evaluation depends on the index of suspicion for TSC. By contrast, we do not evaluate all patients who present with a sporadic AML for LAM. Instead, we would evaluate such patients for LAM only if suggestive findings were present (ie, pulmonary symptoms, abnormal chest radiograph). (See
         <a class="local">
          'Additional testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The postdiagnostic evaluation also includes an assessment of future bleeding risk; this largely informs the decision between treating and surveillance. This is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/90017.html" rel="external">
          "Renal angiomyolipomas (AMLs): Management"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ferry JA, Malt RA, Young RH. Renal angiomyolipoma with sarcomatous transformation and pulmonary metastases. Am J Surg Pathol 1991; 15:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matute Martinez CF, Hamdan A, Sierra David JG, Kolli S. Sporadic, classic-type renal angiomyolipoma with renal vein and inferior vena cava extension: an incidental case. BMJ Case Rep 2021; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parekh V, Shen D. Invasive Renal Angiomyolipoma With Cytologic Atypia. Int J Surg Pathol 2017; 25:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato K, Ueda Y, Tachibana H, et al. Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis. Pathol Res Pract 2008; 204:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii Y, Ajima J, Oka K, et al. Benign renal tumors detected among healthy adults by abdominal ultrasonography. Eur Urol 1995; 27:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rule AD, Sasiwimonphan K, Lieske JC, et al. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis 2012; 59:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002; 168:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kingswood JC, Belousova E, Benedik MP, et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant 2019; 34:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo KC, Kim WT, Ham WS, et al. Trends of presentation and clinical outcome of treated renal angiomyolipoma. Yonsei Med J 2010; 51:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu JH, Hartman TE, Torres VE, Decker PA. Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest 2012; 141:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 2006; 70:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casper KA, Donnelly LF, Chen B, Bissler JJ. Tuberous sclerosis complex: renal imaging findings. Radiology 2002; 225:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cockerell I, Guenin M, Heimdal K, et al. Prevalence of Renal Angiomyolipomas and Spontaneous Bleeding Related to Angiomyolipomas in Tuberous Sclerosis Complex Patients in France and Norway-a Questionnaire Study. Urology 2017; 104:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewalt DH, Sheffield E, Sparagana SP, et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol 1998; 160:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004; 66:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein J, Robbins TO. Renal involvement in tuberous sclerosis. Ann N Y Acad Sci 1991; 615:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres VE, King BF, Holley KE, et al. The kidney in the tuberous sclerosis complex. Adv Nephrol Necker Hosp 1994; 23:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres VE, King BF, McKusick MA, et al. Update on tuberous sclerosis complex. Contrib Nephrol 2001; :33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel U, Simpson E, Kingswood JC, Saggar-Malik AK. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. Clin Radiol 2005; 60:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seyam RM, Bissada NK, Kattan SA, et al. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urology 2008; 72:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein SM, Newell JD Jr, Adamczyk D, et al. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1995; 152:2138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blute ML. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1996; 154:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engels K, Stauber R, Magnussen H, et al. Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women. Eur Urol 2009; 55:755.
          </a>
         </li>
         <li class="breakAll">
          Hornick JL, Pan C-C. PEComa. In: World Health Organization classification of tumours of soft tissue and bone, 4th, Fletcher CDM, Brodge JA, Hogendoorn PCW, Mertens F (Eds), IARC, Lyon 2013. p.230.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siroky BJ, Yin H, Dixon BP, et al. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am J Physiol Renal Physiol 2014; 307:F560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol 2003; 162:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis EL, Palmer JM. Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy. West J Med 1985; 143:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrikovsky BM, Vintzileos AM, Cassidy SB, Egan JF. Tuberous sclerosis in pregnancy. Am J Perinatol 1990; 7:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raft J, Lalot JM, Meistelman C, Longrois D. [Renal angiomyolipoma rupture during pregnancy]. Gynecol Obstet Fertil 2006; 34:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapardiel I, Delafuente-Valero J, Bajo-Arenas JM. Renal angiomyolipoma during pregnancy: review of the literature. Gynecol Obstet Invest 2011; 72:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein KO, Baron J, Colli MJ, et al. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94:2475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould Rothberg BE, Grooms MC, Dharnidharka VR. Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy. Obstet Gynecol 2006; 108:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamboli P, Ro JY, Amin MB, et al. Benign tumors and tumor-like lesions of the adult kidney. Part II: Benign mesenchymal and mixed neoplasms, and tumor-like lesions. Adv Anat Pathol 2000; 7:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martignoni G, Pea M, Rocca PC, Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology 2003; 35:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol 2008; 180:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydin H, Magi-Galluzzi C, Lane BR, et al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 2009; 33:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloom DA, Scardino PT, Ehrlich RM, Waisman J. The significance of lymph nodal involvement in renal angiomyolipoma. J Urol 1982; 128:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulbert JC, Graf R. Involvement of the spleen by renal angiomyolipoma: metastasis or multicentricity? J Urol 1983; 130:328.
          </a>
         </li>
         <li class="breakAll">
          Amin MB. Epithelioid angiomyolipoma. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs, Eble J, Sauter G, Epstein J (Eds), IARC Press, Lyon 2004. p.68.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011; 35:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Kapoor A, Cheon P, et al. Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. Can Urol Assoc J 2020; 14:E527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmiester M, Dolnik A, Kornak U, et al. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. J Pathol Clin Res 2021; 7:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun K, Zhao M, Yao H, et al. Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3. Int J Clin Exp Pathol 2014; 7:8170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol 2010; 34:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei JH, Liu LR, Wei Q, et al. A Four-Year Follow-up Study of Renal Epithelioid Angiomyolipoma: A Multi-Center Experience and Literature Review. Sci Rep 2015; 5:10030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeRoy MA, Rao P. Angiomyolipoma With Epithelial Cysts. Arch Pathol Lab Med 2016; 140:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clin Radiol 2010; 65:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 2011; 118:e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. J Urol 1986; 135:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mouded IM, Tolia BM, Bernie JE, Newman HR. Symptomatic renal angiomyolipoma: report of 8 cases, 2 with spontaneous rupture. J Urol 1978; 119:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albi G, del Campo L, Tagarro D. Wünderlich's syndrome: causes, diagnosis and radiological management. Clin Radiol 2002; 57:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu XF, Hu XH, Zuo QM, et al. A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage. Medicine (Baltimore) 2020; 99:e20167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan JW, Farrelly C, Geoghegan T. What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature. Can Assoc Radiol J 2018; 69:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rimon U, Duvdevani M, Garniek A, et al. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. Clin Radiol 2006; 61:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamakado K, Tanaka N, Nakagawa T, et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 2002; 225:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vabret E, Couchoud C, Lassalle M, Vigneau C. From tuberous sclerosis complex to end stage renal disease: who are these patients? J Nephrol 2021; 34:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport MS, Neville AM, Ellis JH, et al. Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging. Radiology 2011; 260:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka H, Yoshida S, Fujii Y, et al. Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. Int J Urol 2011; 18:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry HS, Davenport MS, Nieman CM, et al. Histogram analysis of small solid renal masses: differentiating minimal fat angiomyolipoma from renal cell carcinoma. AJR Am J Roentgenol 2012; 198:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasiwimonphan K, Takahashi N, Leibovich BC, et al. Small (&lt;4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology 2012; 263:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho CL, Chen S, Ho KM, et al. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma. Clin Nucl Med 2012; 37:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schieda N, Kielar AZ, Al Dandan O, et al. Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation. Clin Radiol 2015; 70:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song S, Park BK, Park JJ. New radiologic classification of renal angiomyolipomas. Eur J Radiol 2016; 85:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson MP, Patel D, Murad MH, et al. Diagnostic Performance of MRI in the Detection of Renal Lipid-Poor Angiomyolipomas: A Systematic Review and Meta-Analysis. Radiology 2020; 296:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartman DS, Goldman SM, Friedman AC, et al. Angiomyolipoma: ultrasonic-pathologic correlation. Radiology 1981; 139:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidhar K, McGahan JP, Early HM, et al. Renal Cell Carcinomas: Sonographic Appearance Depending on Size and Histologic Type. J Ultrasound Med 2016; 35:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao H, Fang L, Chen L, et al. The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma. J Ultrasound Med 2022; 41:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park BK. Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat. AJR Am J Roentgenol 2017; 209:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman SG, Gan YU, Mortele KJ, et al. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology 2006; 240:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int 2010; 105:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonzanini M, Pea M, Martignoni G, et al. Preoperative diagnosis of renal angiomyolipoma: fine needle aspiration cytology and immunocytochemical characterization. Pathology 1994; 26:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pea M, Bonetti F, Martignoni G, et al. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol 1998; 22:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiner A, Daneshmand S, Bayne A, et al. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int J Surg Pathol 2010; 18:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 2012; 36:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecciarini L, Cangi MG, Lo Cunsolo C, et al. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. Genes Chromosomes Cancer 2007; 46:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012; 36:1327.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 131412 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1928559" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Renal angiomyolipoma with sarcomatous transformation and pulmonary metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33727284" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sporadic, classic-type renal angiomyolipoma with renal vein and inferior vena cava extension: an incidental case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27596442" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Invasive Renal Angiomyolipoma With Cytologic Atypia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18547741" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7744154" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Benign renal tumors detected among healthy adults by abdominal ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22398108" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352384" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Contemporary diagnosis and management of renal angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29697822" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20635448" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends of presentation and clinical outcome of treated renal angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737494" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17003820" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12409579" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Tuberous sclerosis complex: renal imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28232177" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of Renal Angiomyolipomas and Spontaneous Bleeding Related to Angiomyolipomas in Tuberous Sclerosis Complex Patients in France and Norway-a Questionnaire Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9628635" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Renal lesion growth in children with tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327383" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Renal angiomyolipomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2039157" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renal involvement in tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8154365" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The kidney in the tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11688402" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Update on tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16038693" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805573" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16210669" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8520787" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8912787" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18835088" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18835088" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920756" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12547707" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4082575" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2184812" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tuberous sclerosis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16996772" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : [Renal angiomyolipoma rupture during pregnancy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876331" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal angiomyolipoma during pregnancy: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989605" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17018483" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10640201" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Benign tumors and tumor-like lesions of the adult kidney. Part II: Benign mesenchymal and mixed neoplasms, and tumor-like lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14660101" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Renal pathology in the tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635231" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18852677" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7154190" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The significance of lymph nodal involvement in renal angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6876283" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Involvement of the spleen by renal angiomyolipoma: metastasis or multicentricity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6876283" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Involvement of the spleen by renal angiomyolipoma: metastasis or multicentricity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21263237" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33213697" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33180365" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25550868" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20410812" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25939249" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Four-Year Follow-up Study of Renal Epithelioid Angiomyolipoma: A Multi-Center Experience and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27232352" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Angiomyolipoma With Epithelial Cysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20103431" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The radiological diagnosis and treatment of renal angiomyolipoma-current status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21071977" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Tuberous sclerosis complex renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3520013" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The management of renal angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/660745" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Symptomatic renal angiomyolipoma: report of 8 cases, 2 with spontaneous rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384111" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Wünderlich's syndrome: causes, diagnosis and radiological management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32443333" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29804911" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16713423" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12354988" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130718" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : From tuberous sclerosis complex to end stage renal disease: who are these patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21555349" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21815937" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268181" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Histogram analysis of small solid renal masses: differentiating minimal fat angiomyolipoma from renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22344404" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Small (&lt;4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996247" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25468637" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27666625" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : New radiologic classification of renal angiomyolipomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32602827" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Diagnostic Performance of MRI in the Detection of Renal Lipid-Poor Angiomyolipomas: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7220890" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Angiomyolipoma: ultrasonic-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26740493" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Renal Cell Carcinomas: Sonographic Appearance Depending on Size and Histologic Type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34499770" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28726505" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709793" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Renal masses in the adult patient: the role of percutaneous biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19493268" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8090589" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Preoperative diagnosis of renal angiomyolipoma: fine needle aspiration cytology and immunocytochemical characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9500218" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403547" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Distinctive morphology of renal cell carcinomas in tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22892601" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17285572" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22895266" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
